# The MYC-SWI/SNF connection in rhabdoid tumors

> **NIH NIH R01** · VANDERBILT UNIVERSITY · 2024 · $353,241

## Abstract

PROJECT SUMMARY
Rhabdoid tumors are rare and aggressive pediatric cancers with high rates of mortality and few treatment
options. Most children diagnosed with rhabdoid tumors will die within 18 months of diagnosis, often after
grueling treatment regimens that involve combinations of surgery, chemotherapy, and radiation. The
molecular basis of rhabdoid tumors is remarkably simple, and involves loss of a single tumor suppressor—
SMARCB1—which encodes the SNF5 component of the SWI/SNF chromatin remodeler. Identification of
SNF5 loss as the driver of rhabdoid tumors was a major breakthrough in understanding the disease, but
raises the question of how the absence of SNF5 promotes tumorigenic programs and whether there are
actionable targets for therapeutic intervention in these cancers. The premise of this project is that loss of
SNF5 causes rhabdoid tumors, at least in part, by activating c-MYC, an oncoprotein transcription factor with
extensive ties to cancer. Supporting this premise are preliminary data showing: (i) an extensive overlap
between the primary transcriptional effects of MYC inhibition and SNF5 re-introduction in rhabdoid tumor
cells, (ii) physical interactions between MYC and SWI/SNF components that are blocked by SNF5, (iii) the
ability of SNF5 to separately inhibit DNA binding by MYC, (iv) MYC-dependent recruitment of a core SWI/
SNF component to chromatin in rhabdoid tumor cells, and (v) an essential role for MYC in rhabdoid tumor
cell survival and transformation. Together, these data explain the recurrent presence of MYC target gene
signatures in rhabdoid tumor patients, and support a model in which loss of SNF5 stimulates a productive
interaction of MYC on chromatin with 'residual' SWI/SNF complexes—which in turn drives key tumorigenic
transcriptional programs in these malignancies. The goal of this project is to characterize the MYC–SWI/
SNF connection in rhabdoid tumor cells, and determine its role in sculpting the rhabdoid transcriptome.
Specific Aim 1 will use a combination of biochemical, genetic, and genomic approaches to define
components of the MYC–SWI/SNF complex and to characterize their recruitment to sites across the
rhabdoid genome. Specific Aim 2 will combine high resolution transcriptomic analyses with cell-based
assays to reveal primary transcriptional events that are controlled via the MYC–SWI/SNF interaction in
rhabdoid tumor cells and to decipher the underlying mechanisms. Completion of these studies will
rigorously challenge the idea that MYC is a defacto driver of oncogenic transcriptional processes in these
cancers. These studies will also expose whether MYC inhibitors are likely to be an effective therapeutic
option in rhabdoid cancers, and will establish a paradigm for how tumor-associated mutations in SWI/SNF—
which occur in 20% of all cancers—intersect with classic oncogenic pathways to drive malignancy.

## Key facts

- **NIH application ID:** 10853009
- **Project number:** 5R01CA247833-05
- **Recipient organization:** VANDERBILT UNIVERSITY
- **Principal Investigator:** William Patrick Tansey
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $353,241
- **Award type:** 5
- **Project period:** 2020-06-01 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10853009

## Citation

> US National Institutes of Health, RePORTER application 10853009, The MYC-SWI/SNF connection in rhabdoid tumors (5R01CA247833-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10853009. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*